Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.62 |
| ▸ | WNT1 | P04628 | 14/20 | 0.62 |
| ▸ | CLK2 | P49760 | 7/20 | 0.61 |
| ▸ | CLK3 | P49761 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523185 | 0.97 | DYRK1A (0.63) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL6221664 | 0.93 | DYRK1A (0.68) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL5716625 | 0.85 | DYRK1A (0.56) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL4523340 | 0.85 | DYRK1A (0.52) | DYRK1AWNT1CLK2CLK3 | |
| Hydrochloric Acid SCHEMBL951130 | 0.85 | DYRK1A (0.55) | DYRK1AWNT1CLK2CLK3 | |
| Hydrochloric Acid SCHEMBL4529550 | 0.85 | DYRK1A (0.55) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL5716427 | 0.82 | DYRK1A (0.82) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL955157 | 0.82 | DYRK1A (0.54) | DYRK1AWNT1CLK2CLK3 | |
| Hydrochloric Acid SCHEMBL952393 | 0.81 | DYRK1A (0.80) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14785604 | 0.81 | DYRK1A (0.84) | DYRK1AWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | claimed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | claimed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | DYRK1A 425/4885WNT1 364/4885CLK2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.